TY - JOUR
T1 - Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy
T2 - A post hoc analysis of the RENAAL trial results
AU - Remuzzi, Giuseppe
AU - Ruggenenti, Piero
AU - Perna, Annalisa
AU - Dimitrov, Borislav D.
AU - De Zeeuw, Dick
AU - Hille, Darcy A.
AU - Shahinfar, Shahnaz
AU - Carides, George W.
AU - Brenner, Barry M.
PY - 2004/12
Y1 - 2004/12
N2 - Renin angiotensin system inhibitor therapy is seldom offered to individuals who have diabetes and advanced chronic kidney disease because of safety concerns. In this post hoc, secondary analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, angiotensin antagonism risk/benefit profile was assessed in 1513 individuals with type 2 diabetes and overt nephropathy. Incidence of ESRD, hospitalizations for heart failure, withdrawals for adverse events, and proteinuria during losartan or conventional treatment were compared within three tertiles of baseline serum creatinine concentration (highest, 2.1 to 3.6 mg/dl; middle, 1.6 to 2.0 mg/dl; lowest, 0.9 to 1.6 mg/dl). Losartan decreased the risk of ESRD by 24.6, 26.3, and 35.3% in highest, middle, and lowest tertiles, respectively. For every 100 patients with serum creatinine >2.0, 1.6 to 2.0, or
AB - Renin angiotensin system inhibitor therapy is seldom offered to individuals who have diabetes and advanced chronic kidney disease because of safety concerns. In this post hoc, secondary analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, angiotensin antagonism risk/benefit profile was assessed in 1513 individuals with type 2 diabetes and overt nephropathy. Incidence of ESRD, hospitalizations for heart failure, withdrawals for adverse events, and proteinuria during losartan or conventional treatment were compared within three tertiles of baseline serum creatinine concentration (highest, 2.1 to 3.6 mg/dl; middle, 1.6 to 2.0 mg/dl; lowest, 0.9 to 1.6 mg/dl). Losartan decreased the risk of ESRD by 24.6, 26.3, and 35.3% in highest, middle, and lowest tertiles, respectively. For every 100 patients with serum creatinine >2.0, 1.6 to 2.0, or
UR - http://www.scopus.com/inward/record.url?scp=9644294206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9644294206&partnerID=8YFLogxK
U2 - 10.1097/01.ASN.0000146423.71226.0C
DO - 10.1097/01.ASN.0000146423.71226.0C
M3 - Article
C2 - 15579515
AN - SCOPUS:9644294206
VL - 15
SP - 3117
EP - 3125
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 12
ER -